Elanco Animal Health (NYSE:ELAN) Updates Q1 2026 Earnings Guidance

Elanco Animal Health (NYSE:ELAN) updated its first quarter 2026 earnings guidance on Tuesday. The company provided earnings per share guidance of 0.330-0.36 for the period, compared to the consensus earnings per share estimate of 0.350. The company issued revenue guidance of $1.3 billion-$1.3 billion, compared to the consensus revenue estimate of $1.3 billion. Elanco Animal Health also updated its FY 2026 guidance to 1.000-1.060 EPS.

Elanco Animal Health Stock Performance

NYSE:ELAN opened at $24.72 on Tuesday. The company has a market cap of $12.28 billion, a price-to-earnings ratio of 412.07, a PEG ratio of 3.73 and a beta of 1.87. Elanco Animal Health has a fifty-two week low of $8.02 and a fifty-two week high of $26.08. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.23 and a current ratio of 2.40. The stock has a fifty day moving average price of $23.90 and a 200-day moving average price of $21.55.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings results on Tuesday, February 24th. The company reported $0.13 EPS for the quarter, beating analysts’ consensus estimates of $0.11 by $0.02. Elanco Animal Health had a return on equity of 7.41% and a net margin of 0.78%.The business had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.09 billion. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. As a group, equities analysts anticipate that Elanco Animal Health will post 0.91 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently weighed in on ELAN shares. UBS Group upped their price target on shares of Elanco Animal Health from $27.00 to $30.00 and gave the stock a “buy” rating in a report on Thursday, January 29th. Morgan Stanley upped their target price on Elanco Animal Health from $18.00 to $22.00 and gave the stock an “equal weight” rating in a research note on Thursday, December 18th. JPMorgan Chase & Co. lifted their price target on Elanco Animal Health from $24.00 to $28.00 and gave the company an “overweight” rating in a research note on Thursday, February 19th. Piper Sandler upgraded Elanco Animal Health from a “neutral” rating to an “overweight” rating and upped their price objective for the stock from $24.00 to $30.00 in a research report on Thursday, January 22nd. Finally, Barclays assumed coverage on shares of Elanco Animal Health in a report on Tuesday, December 9th. They issued an “overweight” rating and a $30.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $25.89.

Insider Activity

In other news, CEO Jeffrey N. Simmons purchased 22,000 shares of the business’s stock in a transaction on Thursday, December 11th. The shares were acquired at an average price of $21.75 per share, with a total value of $478,500.00. Following the completion of the transaction, the chief executive officer owned 167,000 shares of the company’s stock, valued at $3,632,250. The trade was a 15.17% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Rajeev A. Modi bought 4,500 shares of the business’s stock in a transaction that occurred on Thursday, December 11th. The shares were acquired at an average price of $21.33 per share, for a total transaction of $95,985.00. Following the transaction, the insider owned 123,082 shares in the company, valued at $2,625,339.06. This represents a 3.79% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have bought a total of 43,450 shares of company stock worth $937,883 over the last quarter. Company insiders own 0.89% of the company’s stock.

Hedge Funds Weigh In On Elanco Animal Health

A number of institutional investors and hedge funds have recently modified their holdings of ELAN. Dimensional Fund Advisors LP increased its stake in shares of Elanco Animal Health by 1.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 25,082,545 shares of the company’s stock valued at $567,622,000 after acquiring an additional 373,869 shares in the last quarter. UBS Group AG raised its holdings in shares of Elanco Animal Health by 56.7% during the third quarter. UBS Group AG now owns 16,468,148 shares of the company’s stock valued at $331,669,000 after purchasing an additional 5,961,457 shares during the period. Fuller & Thaler Asset Management Inc. boosted its position in shares of Elanco Animal Health by 16.1% during the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 5,771,622 shares of the company’s stock worth $130,612,000 after purchasing an additional 799,745 shares in the last quarter. Invesco Ltd. grew its stake in shares of Elanco Animal Health by 336.0% in the 4th quarter. Invesco Ltd. now owns 4,789,037 shares of the company’s stock valued at $108,376,000 after buying an additional 3,690,735 shares during the period. Finally, Goldman Sachs Group Inc. increased its position in Elanco Animal Health by 104.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock valued at $50,268,000 after buying an additional 2,445,872 shares in the last quarter. 97.48% of the stock is currently owned by institutional investors.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.